Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes

“…The soluble form of RAGE measured in peripheral blood may be released by several cell types, such as endothelial cells and circulating leucocytes, and may result from cleavage of the full-length native membranous receptor by proteinases like matrix metalloproteinases and/or from the expression of an RAGE splice gene variant that encodes the amino-terminally truncated soluble form of the receptor [11][12][13]25]. Several novel splice variants of RAGE, all encoding truncated sRAGE, have recently been identified.…”

“…Recent studies have identified novel gene splice variants of the human receptor RAGE [11][12][13]. Three major RAGE mRNA variants have been identified.…”

Dietary coconut kernel protein beneficially modulates NFκB and RAGE expression in streptozotocin induced diabetes in rats

“…The receptor for AGE (RAGE),an integral membrane protein, forming the central binding site on the cell surface for AGEs, is a multi ligand and signal transduction receptor belonging to immunoglobulin superfamily and can be unregulated under various pathological conditions (Katz et al 2005;Ziyadeh et al 1997;Park et al 2004;Schmidt et al 2000). The engagement of AGEs to RAGE leads to the activation of the transcription factor, nuclear factor kappa B (NFkB) and subsequent expression of NFkB regulated cytokines.…”

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes

“…Among them, the receptor for AGE (RAGE) is the best characterised molecule [3]. RAGE belongs to the immunoglobulin superfamily of cell-surface molecules and recent studies have identified novel splice variants of the human RAGE receptor [4][5][6]. Three major RAGE (also known as AGER) mRNA variants have been identified.…”

“…On the other hand, studies that measured esRAGE found lower esRAGE levels in type 1 and type 2 diabetic patients [13,14]. Since there are a number of distinct splice variants of sRAGE [4][5][6], it has been suggested that esRAGE might constitute only part, but not all of the human sRAGE in plasma. Relatively little is known about factors that influence endogenous circulating sRAGE levels; however, an association with glycaemic control has recently been reported [15].…”